Dyne Therapeutics’ (DYN) “Overweight” Rating Reaffirmed at Piper Sandler

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “overweight” rating reissued by equities researchers at Piper Sandler in a report issued on Monday, Benzinga reports. They currently have a $53.00 price target on the stock. Piper Sandler’s price target suggests a potential upside of 39.33% from the stock’s current price.

A number of other equities research analysts also recently weighed in on DYN. Oppenheimer restated an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Morgan Stanley increased their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Trading Up 4.0 %

Shares of NASDAQ DYN opened at $38.04 on Monday. The business has a 50-day moving average of $41.07 and a 200-day moving average of $33.66. The firm has a market capitalization of $3.32 billion, a price-to-earnings ratio of -9.22 and a beta of 1.07. Dyne Therapeutics has a 12 month low of $6.40 and a 12 month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, analysts predict that Dyne Therapeutics will post -2.96 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, COO Susanna Gatti High sold 8,976 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the transaction, the chief operating officer now owns 131,636 shares in the company, valued at $4,529,594.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Dyne Therapeutics news, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Richard William Scalzo sold 1,390 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now directly owns 98,568 shares in the company, valued at $3,405,524.40. The disclosure for this sale can be found here. Insiders sold 12,705 shares of company stock worth $437,701 in the last three months. 20.77% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DYN. Nisa Investment Advisors LLC increased its position in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares during the period. Amalgamated Bank grew its holdings in shares of Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after acquiring an additional 796 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of Dyne Therapeutics by 28.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after acquiring an additional 1,291 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new position in shares of Dyne Therapeutics in the 2nd quarter valued at approximately $203,000. Finally, Farallon Capital Management LLC bought a new stake in shares of Dyne Therapeutics during the second quarter valued at approximately $212,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.